

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 468-30

C# M#

OMURA et al.

.C. / Art Unit: 1652


Serial No. 09/914,286

Examiner: N.T. Nashed

Filed: August 24, 2001

Date: September 21, 2004

Title: AVERMECTIN AGLYCON SYNTHASE GENES

1652
#

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

AMENDMENT UNDER 37 CFR § 1.111

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

☐ **Correspondence Address Indication Form Attached.****Fees are attached as calculated below:**

Total effective claims after amendment **18** minus highest number
previously paid for **57** (at least 20) = **0** x \$ **18.00** \$ **0.00**

Independent claims after amendment **4** minus highest number
previously paid for **17** (at least 3) = **0** x \$ **86.00** \$ **0.00**

If proper multiple dependent claims now added for first time, add \$290.00 (ignore improper) \$ **0.00**

Petition is hereby made to extend the current due date so as to cover the filing date of this
paper and attachment(s) (\$110.00/1 month; \$420.00/2 months; \$950.00/3 months) \$ **420.00**

Terminal disclaimer enclosed, add \$ 110.00 \$ **0.00**

☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$770.00) \$ **0.00**

☐ Please enter the previously unentered, filed

☐ Submission attached

Subtotal \$ **420.00**

If "small entity," then enter half (1/2) of subtotal and subtract -\$ **0.00**

☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ **0.00**

Assignment Recording Fee (\$40.00) \$ **0.00**

Other: **SUBMISSION OF FORMAL DRAWINGS ALONG WITH FIGS. 1 AND 2A-2C; AND FIGURE 2B WITH CORRECTIONS MARKED IN RED** **0.00**

TOTAL FEE ENCLOSED \$ **420.00**

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
GRT:ap

NIXON & VANDERHYE P.C.
By Atty: Gary R. Tanigawa, Reg. No. 43,180

Signature: 



1652
/hw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

OMURA et al.

Appln. No. 09/914,286

Filed: August 24, 2001

FOR: AVERMECTIN AGLYCON SYNTHASE GENES

Confirmation No.: 2354

Atty. Ref.: 468-30

T.C. / Art Unit: 1652

Examiner: N.T. Nashed

* * *

AMENDMENT UNDER 37 CFR § 1.111

September 21, 2004

Mail Stop Amendment

Hon. Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In response to the pending Office Action mailed April 21, 2004, entry and consideration of the following amendments and remarks are respectfully requested.

Amended portions of the **specification** are presented on page 2.

A typographical error on page 47 is corrected.

Figure 2B is corrected.

The **claims** are presented on pages 3-5.

Claims 2, 16, 32 and 34-38 are amended.

Claims 1, 31, 39-42, 44 and 49-56 are canceled without prejudice or disclaimer.

Remarks begin on page 6.

09/22/2004 EFLURES 00000050 09914286

01 FC:1252

420.00 UP